Recent Updates
Recently added Catalysts

APD125

Phase 2

Primary Insomnia | Small molecule | Other |Pfizer, Inc.|Last Updated: Dec 23, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment744
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00664664Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance InsomniaPHASE2 COMPLETED 744Apr 1, 2008Nov 1, 2008Dec 23, 2020 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
APD125DRUGsoft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
PlaceboDRUGsoft gelatin capsule, daily dosing for up to 3 weeks
Unlock Study Design Details